<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03648970</url>
  </required_header>
  <id_info>
    <org_study_id>IND012018</org_study_id>
    <nct_id>NCT03648970</nct_id>
  </id_info>
  <brief_title>Indonesia Pravastatin to Prevent Preeclampsia Study</brief_title>
  <acronym>INOVASIA</acronym>
  <official_title>Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitas Airlangga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitas Airlangga</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND Preeclampsia is a major cause of maternal and neonatal morbidity worldwide. There
      is currently no cure for preeclampsia, the only definitive treatment is termination of
      pregnancy by induction of labour or caesarean section. Statin has been proposed to represent
      a new approach to improve disease outcome/prevent preeclampsia based on its multilayered
      activity toward pregnancy protection, including: protection of vascular endothelial cells
      survival, induce expression of heme oxygenase 1 (HO-1), inhibiting the release of soluble
      FMS-like tirosine kinase-1 (sFlt-1) and soluble endoglin (sEng), two main culprits in the
      pathophysiology of preeclampsia.

      OBJECTIVE The aim of this study is to observe the effect of pravastatin administration in
      patients with high risk of preeclampsia in order to reduce maternal and neonatal mortality
      and morbidity.

      METHODS This is a prospective randomized controlled clinical trial. The research will be held
      in 5 maternal fetal medicine centers in Indonesia (multicenter study). The recruitment will
      be done by permuted block random sampling methods, with sample size around 280 patients
      divides into two group. Patients with high risk of preeclampsia will be randomized either to
      get pravastatin 2 x 20 mg per oral and aspirin 1 x 80 mg (treatment group) or low dose
      aspirin only (control group). The patient will be followed regularly until delivery to obtain
      detailed maternal and neonatal outcome.

      OUTCOME Primary Outcomes: Maternal preeclampsia, severe preeclampsia, gestational
      hypertension, indicated preterm delivery less than 37 weeks, indicated preterm delivery less
      than 34 weeks, maternal complications, length of hospital stay, and any serious adverse
      event.

      Secondary Outcomes: Composite fetal/neonatal mortality and morbidity (stillbirth, neonatal
      death, respiratory distress syndrome, intracerebral hemorrhage, neonatal sepsis, intra
      uterine growth restriction [Small for Gestational Age (SGA) &lt; 5th centile], and necrotizing
      enterocolitis), birthweight, birthweight percentile, level of care (well baby, intermediate,
      NICU), NICU length of stay, ventilator usage, and length of perinatal hospital stay.

      KEYWORDS: pravastatin, preeclampsia, neonatal mortality, neonatal morbidity
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter Randomized Non Blinded Trial comparing low dose aspirin versus low dose aspirin and pravastatin in patients with high risk developing preeclampsia</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The diagnosis is made by resident unaware of the medication patients received</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>From date of randomization until date of delivery</time_frame>
    <description>Including preeclampsia, preeclampsia with severe features, and gestational hypertension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>20 - 34 weeks, and 34 - 37 weeks</time_frame>
    <description>Including indicated preterm delivery &lt; 34 weeks and &lt; 37 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal complication</measure>
    <time_frame>From date of randomization until date of delivery</time_frame>
    <description>Any maternal complication caused by preeclampsia: eclampsia, seizure, HELLP syndrome, acute pulmonary edema, acute kidney injury, Cardivascular accident, liver failure, sepsis, and pneumonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perinatal outcome</measure>
    <time_frame>At delivery</time_frame>
    <description>Gestational age at birth (days), birthweight (gram), birthweight percentile (INTERGROWTH), Apgar Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity and mortality</measure>
    <time_frame>At delivery</time_frame>
    <description>stillbirths, neonatal death, respiratory distress syndrome, intracerebral hemorrhage, neonatal sepsis, necrotizing enterocolitis, length NICU admission, and length of stay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The side effect of Pravastatin</measure>
    <time_frame>Up to 6 month after birth</time_frame>
    <description>Including adverse reactions, Serious Adverse Event (SAE), and Suspected Unexpected Serious Adverse Reaction (SUSAR)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Pravastatin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>The participant will be given pravastatin 2 x 20 mg per oral daily</description>
    <arm_group_label>Pravastatin Treatment Group</arm_group_label>
    <other_name>Pravastatin Sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational Age 10 wk - 19 wk 6 day

          -  History of previous preeclampsia requiring birth &lt; 37 weeks (risk 30%), or

          -  Patients with a combination of at least 2 major risk factors plus an abnormal uterine
             artery Doppler at 11-20 weeks gestation (risk preeclampsia 30%):

               -  Major clinical risk factors (Obesity, strong family history of preeclampsia
                  [mother or sister], maternal age &gt; 40 years old, chronic hypertension, Policystic
                  Ovarian Syndrome (PCOS), Chronic kidney disease, diabetes mellitus, multiple
                  pregnancies, first pregnancy, pregnancy interval more than 10 years, new
                  partner/husband, Reproductive technologies (IVF pregnancy), heritable
                  thrombophilias, Booking Blood pressure &gt;130/80 mmHg, family history of early
                  onset cardiovascular disease, lower socioeconomic status)

               -  Abnormal uterine artery Doppler defined as (Second trimester screening:

        average resistance index &gt; 0.58 and/or or early-diastolic diastolic notch. First trimester
        screening: Pulsatility index &gt; 95th centile or PI &gt; 1.5) or:

          -  First trimester screening (11+0 to 14+1 weeks): Combination of maternal risk factors,
             elevated MAP, and increased Uterine artery pulsatility index (UTPI).

          -  Second trimester screening (19+0 to 24+6 weeks): Combination of maternal risk factors,
             elevated MAP, and increased Uterine artery pulsatility index (UTPI).

          -  Combination of elevated mean arterial pressure (MAP &gt; 90 mmHg) in the second trimester
             with abnormal uterine artery Doppler

          -  Combination elevated booking blood pressure (&gt; 130/85 mmHg) with abnormal uterine
             artery Doppler

          -  Live fetus, no detectable fetal anomaly

        Exclusion Criteria:

          -  Condition where the pregnancies should be terminated within 48 hours, on the basis of
             any indication (patients consume pravastatin less than 2 days).

          -  Contraindication to the statin use:

               -  Hypersensitivity to pravastatin

               -  Active liver disease

               -  Pre pregnant renal insufficiency/kidney failure (history of hemodialysis)

          -  Current use of statin

          -  Participation in any other controlled trial of investigational medical products in
             pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Ilham Aldika Akbar, MD, OBGYN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Airlangga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Ilham Aldika Akbar, MD, OBGYN</last_name>
    <phone>+6281703270900</phone>
    <email>dokter_aldi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gustaaf Dekker, MD, PhD</last_name>
    <phone>+61881829306</phone>
    <email>gustaaf.dekker@adelaide.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanglah General Hospital</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Saktika Mulyana, MD, OBGYN</last_name>
      <email>ryanmul83@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ryan Saktika Mulyana, MD, OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evert Pangkahila, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Moewardi Hospital</name>
      <address>
        <city>Surakarta</city>
        <state>Central Java</state>
        <zip>57126</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muhammad Adrianes Bachnas, MD, OBGYN</last_name>
      <phone>+628122692928</phone>
      <email>bachnasadri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Adrianes Bachnas, MD, OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Edwin, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramelan Naval Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <zip>60244</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agung Sunarko Putra, MD, OBGYN</last_name>
      <phone>+62811257852</phone>
      <email>dr.agung_sp@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Agung Sunarko Putra, MD, OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frans OH Prasetyadi, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Soetomo Hospital</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <zip>60285</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Ilham Aldika Akbar, MD, OBGYN</last_name>
      <phone>+6281703270900</phone>
      <email>dokter_aldi@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adam Malik General Hospital</name>
      <address>
        <city>Medan</city>
        <state>North Sumatra</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dudy Aldiansyah</last_name>
      <email>dudya141277@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dudy Aldiansyah, MD, OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Makmur Sitepu, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Wahidin Sudirohusodo General Hospital</name>
      <address>
        <city>Makasar</city>
        <state>South Sulawesi</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deviana Soraya Riu, MD, OBGYN</last_name>
      <email>virayariu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Deviana Soraya Riu, MD, OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Theresia Wawengkang, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hasan Sadikin General Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Alamsyah Azis, MD, Obgyn</last_name>
      <email>alamsyahaziz9119@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Alamsyah Azis, MD, Obgyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanes Cornelius Mose, MD, OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Ahmed A, Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Br J Pharmacol. 2015 Mar;172(6):1574-86. doi: 10.1111/bph.12977. Review.</citation>
    <PMID>25303561</PMID>
  </reference>
  <reference>
    <citation>Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation. 2014 Jan;21(1):4-14. doi: 10.1111/micc.12079. Review.</citation>
    <PMID>23890192</PMID>
  </reference>
  <reference>
    <citation>Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007 Apr 3;115(13):1789-97. Epub 2007 Mar 26.</citation>
    <PMID>17389265</PMID>
  </reference>
  <reference>
    <citation>Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D'Alton M, Hankins G; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016 Jun;214(6):720.e1-720.e17. doi: 10.1016/j.ajog.2015.12.038. Epub 2015 Dec 23.</citation>
    <PMID>26723196</PMID>
  </reference>
  <reference>
    <citation>Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol. 2014 Mar;101-102:153-160. doi: 10.1016/j.jri.2013.12.120. Epub 2014 Jan 16. Review.</citation>
    <PMID>24503248</PMID>
  </reference>
  <reference>
    <citation>Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem Soc Trans. 2009 Dec;37(Pt 6):1237-42. doi: 10.1042/BST0371237.</citation>
    <PMID>19909254</PMID>
  </reference>
  <reference>
    <citation>Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation. 2008 Jan 15;117(2):231-41. doi: 10.1161/CIRCULATIONAHA.107.698316. Review.</citation>
    <PMID>18195184</PMID>
  </reference>
  <reference>
    <citation>Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 2001 Jan 20;357(9251):209-15. Review.</citation>
    <PMID>11213110</PMID>
  </reference>
  <reference>
    <citation>Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001 Sep;38(3 Pt 2):718-22.</citation>
    <PMID>11566964</PMID>
  </reference>
  <reference>
    <citation>Seki H. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Acta Obstet Gynecol Scand. 2014 Oct;93(10):959-64. doi: 10.1111/aogs.12473. Epub 2014 Sep 17.</citation>
    <PMID>25139038</PMID>
  </reference>
  <reference>
    <citation>Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008 Apr;51(4):970-5. doi: 10.1161/HYPERTENSIONAHA.107.107607. Epub 2008 Feb 7. Review.</citation>
    <PMID>18259009</PMID>
  </reference>
  <reference>
    <citation>Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007 Oct;64(4):496-509. Epub 2007 May 15.</citation>
    <PMID>17506782</PMID>
  </reference>
  <reference>
    <citation>Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014 Apr;4(2):97-104. doi: 10.1016/j.preghy.2014.02.001. Epub 2014 Feb 15.</citation>
    <PMID>26104417</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997 Feb;18(1):4-25. Review.</citation>
    <PMID>9034784</PMID>
  </reference>
  <reference>
    <citation>Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014 Jun;36(6):506-509. doi: 10.1016/S1701-2163(15)30565-X. Review.</citation>
    <PMID>24927189</PMID>
  </reference>
  <reference>
    <citation>von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014 Aug;16(8):454. doi: 10.1007/s11906-014-0454-8. Review.</citation>
    <PMID>24915961</PMID>
  </reference>
  <reference>
    <citation>Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649-58.</citation>
    <PMID>12618519</PMID>
  </reference>
  <reference>
    <citation>Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol. 2011 Jan;31(1):33-46. doi: 10.1016/j.semnephrol.2010.10.004. Review.</citation>
    <PMID>21266263</PMID>
  </reference>
  <reference>
    <citation>Hod T, Cerdeira AS, Karumanchi SA. Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med. 2015 Aug 20;5(10). pii: a023473. doi: 10.1101/cshperspect.a023473. Review.</citation>
    <PMID>26292986</PMID>
  </reference>
  <reference>
    <citation>Teelucksingh S, El-Youssef J, Sohan K, Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy. Reprod Toxicol. 2004 Mar-Apr;18(2):299-300.</citation>
    <PMID>15019727</PMID>
  </reference>
  <reference>
    <citation>WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization; 2011.</citation>
    <PMID>23741776</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitas Airlangga</investigator_affiliation>
    <investigator_full_name>Muhammad Ilham Aldika Akbar, MD, OBGYN</investigator_full_name>
    <investigator_title>Principal Investigator, MFM Consultant</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Pravastatin</keyword>
  <keyword>Maternal morbidity</keyword>
  <keyword>Neonatal mortality</keyword>
  <keyword>Neonatal morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

